Johnson & Johnson
JNJ
Company Profile
Business description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Contact
One Johnson & Johnson Plaza
New BrunswickNJ08933
USAT: +1 732 524-0400
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
140,800
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
The beaten down healthcare giant remains cheap on turnaround potential.
stocks
ASX top pick remains cheap with narrowing brand focus
Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.80 | 63.30 | 0.72% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,136.04 | 271.92 | -1.11% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 64,265.26 | 85.99 | 0.13% |
| NZX 50 Index | 13,184.04 | 69.61 | -0.53% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,631.50 | 68.00 | 0.79% |
| SSE Composite Index | 3,964.24 | 28.98 | -0.73% |